Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (Ecstasy) intoxication: An Event-related fmri study

Neuropsychopharmacology

Volumn 34, Issue 7, 2009, Pages 1641-1648

  Ramaekers, Johannes G ^a   Kuypers, Kim P C ^a   Wingen, Marleen ^a   Heinecke, Armin ^a   Formisano, Elia ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acute; Imaging; MDMA; Prospective memory

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PLACEBO; RECREATIONAL DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG INTOXICATION; EVENT RELATED POTENTIAL; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MEMORY; MEMORY DISORDER; PARIETAL LOBE; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; TASK PERFORMANCE; THALAMUS; VISUAL STIMULATION;

ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; HALLUCINOGENS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PARIETAL LOBE; REACTION TIME; YOUNG ADULT;

EID: 67349270871     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.219     Document Type: Article

References (54)

1. Bedi G, Redman J (2008a). Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol Med 38: 1319-1330.
2. Bedi G, Redman J (2008b). Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean? J Psychopharmacol 22: 872-881.
3. Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('ecstasy') users. Neurology 51: 1532-1537.
4. Burgess PW, Quayle A, Frith CD (2001). Brain regions involved in prospective memory as determined by positron emission tomography. Neuropsychologia 39: 545-555.
5. Burgess PW, Scott SK, Frith CD (2003). The role of the rostral frontal cortex (area 10) in prospective memory: a lateral versus medial dissociation. Neuropsychologia 41: 906-918.
6. Cole JC, Sumnall HR (2003). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
7. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl) 153: 373-379.
8. Dafters RI, Hoshi R, Talbot AC (2004). Contribution of cannabis and MDMA ('ecstasy') to cognitive changes in long-term polydrug users. Psychopharmacology (Berl) 173: 405-410.
9. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
10. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M et al (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
11. den Ouden HE, Frith U, Frith C, Blakemore SJ (2005). Thinking about intentions. Neuroimage 28: 787-796.
12. Einstein GO, McDaniel MA, Thomas R, Mayfield S, Shank H, Morrisette N et al (2005). Multiple processes in prospective memory retrieval: factors determining monitoring versus spontaneous retrieval. J Exp Psychol Gen 134: 327-342.
13. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M et al (2004). Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173: 364-375.
14. Forman SD, Cohen JD, Fitzgerald M, Eddy WF, Mintun MA, Noll DC (1995). Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a clustersize threshold. Magn Reson Med 33: 636-647.
15. Gobel SM, Johansen-Berg H, Behrens T, Rushworth MF (2004). Response-selection-related parietal activation during number comparison. J Cogn Neurosci 16: 1536-1551.
16. Gouzoulis-Mayfrank E, Daumann J (2006). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 20: 188-193.
17. Gouzoulis-Mayfrank E, Daumann J, Sass H (2002). [Chronic neurotoxic damage in ecstasy (MDMA) users. Review of the current state of research]. Nervenarzt 73: 405-421.
18. Halpern JH, Pope Jr HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D (2004). Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135-147.
19. Hanson KL, Luciana M (2004). Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229-246.
20. Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider F (2008). Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol. Doi: 1177/026g8811080g4650 page 1-13.
21. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J (2001a). Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Hum Psychopharmacol 16: 607-612.
22. Heffernan TM, Ling J, Scholey AB (2001b). Subjective ratings of prospective memory deficits in MDMA ('ecstasy') users. Hum Psychopharmacol 16: 339-344.
23. Jager G, de Win MM, van der Tweel I, Schilt T, Kahn RS, van den Brink W et al (2008). Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study. Neuropsychopharmacology 33: 247-258.
24. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008). Plasma pharmacokinetics of 3,4-methylene-dioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30: 320-332.
25. Kubler A, Dixon V, Garavan H (2006). Automaticity and reestablishment of executive controlFan fMRI study. J Cogn Neurosci 18: 1331-1342.
26. Kuypers KP, Ramaekers JG (2005). Transient memory impairment after acute dose of 75 mg 3.4-methylene-dioxymethampheta-mine. J Psychopharmacol 19: 633-639.
27. Kuypers KP, Ramaekers JG (2007). Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology (Berl) 189: 557-563.
28. Kuypers KP, Wingen M, Ramaekers JG (2008). Memory and mood during the night and in the morning after repeated evening doses of MDMA. J Psychopharmacol 22: 895-903.
29. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H (2002). Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68: 195-207.
30. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J et al (1999). Cardiovascular and neuroendocrine effects and pharma-cokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136-145.
31. McDaniel MA, Einstein GO (1993). The importance of cue familiarity and cue distinctiveness in prospective memory. Memory 1: 23-41.
32. McGuire P (2000). Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett 112-113: 153-156.
33. Montgomery C, Fisk JE (2007). Everyday memory deficits in ecstasy-polydrug users. J Psychopharmacol 21: 709-717.
34. Montgomery C, Fisk JE, Newcombe R (2005). The nature of ecstasy-group related deficits in associative learning. Psychopharmacology (Berl) 180: 141-149.
35. Morgan MJ (1999). Memory deficits associated with recreational use of 'ecstasy' (MDMA). Psychopharmacology (Berl) 141: 30-36.
36. Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 15: 230-248.
37. Parrott AC (2000). Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24.
38. Parrott AC (2001). Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16: 557-577.
39. Piazza M, Mechelli A, Butterworth B, Price CJ (2002). Are subitizing and counting implemented as separate or functionally overlapping processes? Neuroimage 15: 435-446.
40. Pinel P, Le Clec HG, van de Moortele PF, Naccache L, Le Bihan D, Dehaene S (1999). Event-related fMRI analysis of the cerebral circuit for number comparison. Neuroreport 10: 1473-1479.
41. Poldrack RA, Fletcher PC, Henson RN, Worsley KJ, Brett M, Nichols TE (2008). Guidelines for reporting an fMRI study. Neuroimage 40: 409-414.
42. Ramaekers JG, Kuypers KP (2006). Acute effects of 3,4-methyle- nedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol. Neuropsychopharmacology 31: 1048-1055.
43. Rendell PG, Gray TJ, Henry JD, Tolan A (2007). Prospective memory impairment in 'ecstasy' (MDMA) users. Psychopharmacology (Berl) 194: 497-504.
44. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott A (2001). Differential effects of ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol 16: 619-625.
45. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC (2003). Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study. J Psychopharmacol 17: 389-396.
46. Sandrini M, Rossini PM, Miniussi C (2004). The differential involvement of inferior parietal lobule in number comparison: a rTMS study. Neuropsychologia 42: 1902-1909.
47. Schnell K, Heekeren K, Schnitker R, Daumann J, Weber J, Hesselmann V et al (2007). An fMRI approach to particularize the frontoparietal network for visuomotor action monitoring: detection of incongruence between test subjects' actions and resulting perceptions. Neuroimage 34: 332-341.
48. Simon NG, Mattick RP (2002). The impact of regular ecstasy use on memory function. Addiction 97: 1523-1529.
49. Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical: New York.
50. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L et al (2006). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211-225.
51. Trimbos I (2007). DIMS jaarbericht 2007: Trimbos Institute (Netherlands Institute of Health and Addiction).
52. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M et al (2001). Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 153: 196-202.
53. Zakzanis KK, Campbell Z, Jovanovski D (2007). The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol 22: 427-435.
54. Zakzanis KK, Young DA, Campbell Z (2003). Prospective memory impairment in abstinent MDMA ('Ecstasy') users. Cogn Neuropsychiatry 8: 141-153.